4,901 trials
Hypogonadism
Primary: Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months — 0.05; 0.06; 0.06; 0.066 Percent…
Type 2 Diabetes
Primary: Area Under the Concentration Versus Time Curve (AUC(0-infinity)) for MK-1006 — 5171; 5588 nM*hr
Dupuytren's Contracture
Primary: Number of Subjects With AUX I and AUX II Detected in Their Blood After a Single Dose of AA4500 — 0 participants
Healthy
Primary: Area Under the Plasma Concentration Curve (AUC) at Steady State for Metronidazole — 217686; 215809 ng*h/ml
Healthy
Primary: Total Dabigatran: Area Under the Curve 0 to Infinity (AUC0-∞) — 1160; 2520; 1440; 2570 ng*hr/mL — p=1.0000
Pancreatic Cancer
Primary: Number of Participants With a Dose-limiting Toxicity (DLT) — 3; 1; 0; 2 participants
Age Related Macular Degeneration
Primary: Change in Baseline to 3 Months in Best Corrected Visual Acuity — -0.01; 0.08 logMAR
Asthma
Primary: Geometric Mean Fold Change From Baseline in Interleukin-5 (IL-5) Concentration From Nasal Exudates and Sputum at 7 Hours Post-allergen Challenge — 2.16; 8.60; 1.69; 8.63…
Tuberculosis
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC [0-t]) — 38.59; 38.81 microgram*hour/milliliter (mcg*h/mL)
Cardiovascular Diseases · Kidney Failure, Chronic
Primary: Dialysis Clearance of Dabigatran — 161; 241; 120; 183 mL/min
Healthy
Primary: Plasma Dipyridamole Maximum Concentration (Cmax) — 2750; 2550; 2550 nanogram/milliliter
Leukemia
Primary: Recommended Phase II Dose of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia — 60; 80; NA mg/m^2 QD
Healthy
Primary: Pharmacokinetics: Maximum Plasma Concentration (Cmax) — 2.62; 2.63 ug/mL
Multiple Myeloma
Primary: Recommended Phase II Dose (RP2D) of the Combination (Dasatinib + Lenalidomide + Dexamethasone) — 140; 25; 40 mg
Healthy
Primary: The Number of Injections With Local Site Reactions (Bleeding, Swelling, Bruising and Erythema). — 0; 51; 0; 0 injections